Valdecoxib: cutaneous and vascular risks.
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D003875:Drug Eruptions; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000890:Anti-Infective Agents; D016861:Cyclooxygenase Inhibitors; D004232:Diuretics; D007555:Isoxazoles; D013449:Sulfonamides